The Lacuna Trial: a double-blind randomized controlled pilot trial of lactoferrin supplementation in the very preterm infant

J Perinatol. 2016 Aug;36(8):666-9. doi: 10.1038/jp.2016.24. Epub 2016 Mar 3.

Abstract

Objective: To determine tolerability of bovine lactoferrin (bLF) in very preterm infants, and whether the intervention can be adequately masked.

Study design: In a single-center masked pilot trial infants under 31 weeks gestation were randomized before 48 h of age to receive milk with 100 mg per day of bLF or control. The primary outcome was feeding tolerance, defined as time to achieve full feeds (140 ml kg(-1) per day). Parents answered a short questionnaire regarding acceptability of the intervention.

Results: Seventy-nine infants were enrolled and analyzed according to intention to treat. There was no effect of bLF on the primary outcome. In addition, mortality, late onset sepsis and other complications of prematurity were no different. Equal numbers of parents in both groups believed their infant received bLF.

Conclusion: We demonstrated that bLF is well tolerated, easy to administer and its presence in prepared milk is not evident. Trial registration number ISRCTN66482337.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Animals
  • Canada
  • Cattle
  • Double-Blind Method
  • Enterocolitis, Necrotizing / drug therapy*
  • Enterocolitis, Necrotizing / mortality
  • Female
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Infant, Premature*
  • Lactoferrin / administration & dosage*
  • Male
  • Neonatal Sepsis / drug therapy*
  • Neonatal Sepsis / mortality
  • Pilot Projects

Substances

  • Lactoferrin

Associated data

  • ISRCTN/ISRCTN66482337